Materialise NV (MTLS) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
Despite positive factors like a share buyback program and strong revenue growth in the Medical segment, challenges persist. The Manufacturing segment struggles with profitability and macroeconomic headwinds. The Software segment faces revenue declines due to its transition. Additionally, the company's dependence on key verticals and economic uncertainties pose risks. While financial metrics show improvement, the cautious outlook on manufacturing and strategic dependencies balance out the positives, leading to a neutral sentiment.
Key Financial Performance
Consolidated Revenue EUR 70.2 million in Q4 2025, up 6.8% year-on-year. Growth driven by strong performance in Materialise Medical, offset by slight declines in Software and Manufacturing.
Gross Profit Margin EUR 40.8 million in Q4 2025, representing 58.1% of revenue, an increase from the previous year due to higher revenue and operational efficiencies.
Adjusted EBIT EUR 4 million in Q4 2025, a margin of 5.7%, compared to a loss of EUR 1.2 million in Q4 2024. Improvement due to increased gross margin and lower operating expenses.
Net Profit EUR 6.2 million in Q4 2025, more than double the EUR 2.9 million in Q4 2024, driven by higher revenue and operational improvements.
Net Cash Position EUR 70.8 million at the end of Q4 2025, an increase of EUR 10 million compared to the end of 2024, supported by positive free cash flow.
Materialise Medical Revenue EUR 37 million in Q4 2025, up 16% year-on-year. Growth driven by a 23% increase in Medical Devices and Services revenue.
Materialise Software Revenue EUR 11 million in Q4 2025, stable year-on-year. Recurring revenue grew by 4%, while nonrecurring revenue declined by 19%.
Materialise Manufacturing Revenue EUR 22.2 million in Q4 2025, down 2% year-on-year due to macroeconomic headwinds, particularly in prototyping.
Adjusted EBITDA EUR 9.5 million in Q4 2025, more than double the EUR 4.3 million in Q4 2024, with a margin of 13.6%. Improvement driven by higher revenue and cost control.
Deferred Revenue EUR 48.8 million at the end of Q4 2025, an increase of EUR 3.5 million in the quarter, consistent with seasonal patterns.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Mimics Flow: Released a new version with enhanced functionality, a new licensing system, and a new pricing structure. The update includes AI algorithms for high-volume applications, improved 3D planning, and a unified platform for case discussions. The licensing system reduces overhead and introduces subscription pricing models.
CO-AM Solutions: Introduced three tailored CO-AM solutions (Professional, NPI, Enterprise) and CO-AM Brix, a low-code automation technology. These solutions aim to enhance workflow automation, interoperability, and productivity in additive manufacturing.
Dual Listing on Euronext Brussels: Completed a dual listing on Euronext Brussels to complement the NASDAQ listing, providing access to a broader European investor audience and operational flexibility.
Aerospace and Defense Projects: Awarded key projects including the SONRISA project for quality assurance in 3D printed aircraft parts and the Eurodrone project for Environmental Control Systems.
Operational Efficiencies: Automated production processes using CO-AM Brix, significantly reducing nesting time, build processing time, and error rates.
Cost Management: Disciplined cost control and targeted cost reduction measures improved profitability despite macroeconomic challenges.
Platform Consolidation: Merged iMaterialise and Materialise Onsite into a single platform to focus on professional 3D printing markets.
Focus on Key Verticals: Shifted focus towards high-growth industries like aerospace and defense, aligning with strategic goals.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Macroeconomic headwinds in manufacturing: Persistent macroeconomic challenges are negatively impacting demand, particularly in prototyping, leading to a 2% year-on-year revenue decline in Q4 2025 and a 13% decline for the full year.
Foreign exchange effects: Unfavorable foreign exchange rates, primarily from a weaker U.S. dollar, have weighed on the company's top line, impacting revenue growth.
Transition to subscription-based software model: The ongoing shift to a cloud and subscription-based business model in the Software segment has led to a 7% decline in annual revenue for 2025, with nonrecurring revenue dropping by 19% in Q4.
Manufacturing segment profitability: The Manufacturing segment reported a negative adjusted EBITDA of minus EUR 4.2 million for 2025, reflecting challenges in achieving profitability amidst declining revenues.
Regulatory and certification challenges in aerospace: Participation in projects like SONRISA and Eurodrone involves complex quality assurance and certification processes, which could pose operational and financial risks.
Dependence on key verticals: The company's strategic focus on high-growth verticals like aerospace and defense introduces risks related to dependency on a limited number of industries for future growth.
Investment in R&D: Increased R&D investments, while necessary for future growth, could strain financial resources if not matched by corresponding revenue growth.
Economic uncertainties in industrial markets: The company anticipates continued macroeconomic headwinds in industrial market segments throughout 2026, which could further impact the Manufacturing segment's performance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Materialise Medical Segment Growth: The Materialise Medical segment is expected to continue growing at a double-digit pace in 2026.
Materialise Software Segment Transition: The Materialise Software segment will complete its transition to a cloud-based subscription business model in 2026 and will continue investments in a broader AM software ecosystem.
Materialise Manufacturing Segment Outlook: The Materialise Manufacturing segment will intensify its shift towards series manufacturing and dedicated focus sectors, but macroeconomic headwinds in the industrial market segment are expected to persist throughout 2026.
Revenue Guidance for 2026: Revenue for 2026 is expected to be in the range of EUR 273 million to EUR 283 million.
Adjusted EBIT Guidance for 2026: Adjusted EBIT for fiscal year 2026 is expected to reach EUR 10 million to EUR 12 million.
Strategic M&A Opportunities: The company will actively pursue strategic M&A opportunities, leveraging its strong financial position with EUR 134 million in cash and cash equivalents, an improved net cash position, and consistently positive operating and free cash flow.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Buyback Program: Materialise announced a share buyback program of up to EUR 30 million. This program started on January 26, 2026. To date, the company has acquired a total of 187,500 shares for a total amount just below USD 1 million.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Are you assuming that Manufacturing is going to be down this year on a year-over-year basis?
A:Yes, the current trends driven by the weaker industrial climate, particularly in Europe, are expected to weigh on manufacturing results, especially in the prototyping segment. However, growth is expected in focus segments like aerospace and defense, though full results of these investments will take time to materialize.
Q:What percentage of manufacturing is for prototyping applications?
A:The company has not disclosed this percentage yet. However, prototyping still represents a significant part of the manufacturing business, even though it is declining quarter after quarter.
Q:Can the company achieve EBITDA breakeven in the Manufacturing business at EUR 90 million in annual sales?
A:The strategy focuses on growth in additive manufacturing and sectors where the company can differentiate and offer unique capabilities, which are expected to generate stronger margins. Additionally, cost optimization efforts will continue in the manufacturing segment and across the company.
Q:Was there anything one-time in Q4 OpEx, and should EUR 39 million in OpEx be modeled for Q1?
A:Q4 OpEx included nonrecurring costs related to the Euronext listing, amounting to around EUR 750,000. General operating costs are typically higher in Q4, so a full-year projection should level out costs across multiple quarters.
Q:Review of Unclear Management Responses
A:The management avoided providing a direct answer to the question about the percentage of manufacturing for prototyping applications, stating that the percentage has not been disclosed yet.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CO Brix
CO Professional
EBIT EUR
EUR cash
EUR income
EUR investment
EUR license
EUR margin
EUR period
EUR share
Eurodrone
NASDAQ
Slide EUR
access
aircraft
automation
buyback program
capital
flow EUR
flow balance
functionality
improvement
income EUR
increase
insole
licensing system
line EUR
listing
margin EBIT
patient milestone
platform
pricing
production
project
result EUR
segment EUR
software
solution
user
MTLS Transcript
Materialise NV (MTLS) Q1 2026 Earnings Call Transcript
Unknown5-7
The earnings call presents a mixed outlook. While there is positive growth in the Medical segment and improved profitability, challenges such as foreign exchange headwinds, macroeconomic uncertainties, and a decline in Manufacturing revenue persist. The transition to a cloud-based model in Software is promising but poses short-term risks. The Q&A highlights sector-specific growth and challenges, but management's avoidance of certain specifics adds uncertainty. With stable revenue and improved margins but persistent headwinds, the overall sentiment is neutral, suggesting minimal short-term stock movement.
Materialise NV (MTLS) Q4 2025 Earnings Call Transcript
Unknown2-19
Despite positive factors like a share buyback program and strong revenue growth in the Medical segment, challenges persist. The Manufacturing segment struggles with profitability and macroeconomic headwinds. The Software segment faces revenue declines due to its transition. Additionally, the company's dependence on key verticals and economic uncertainties pose risks. While financial metrics show improvement, the cautious outlook on manufacturing and strategic dependencies balance out the positives, leading to a neutral sentiment.
Materialise NV (MTLS) Q3 2025 Earnings Call Transcript
Unknown10-28
The earnings call reveals several negative factors: reduced revenue guidance, geopolitical and macroeconomic challenges, unfavorable foreign exchange impacts, and declining revenues in key segments. Despite some positive elements, like growth in the Medical segment and cost control efforts, the overall sentiment is negative due to reduced guidance and ongoing uncertainties, particularly in manufacturing and defense. The Q&A session did not alleviate concerns, with management providing vague responses about future growth and profitability. The lack of clear guidance and the negative financial trends suggest a likely negative stock price reaction.
Materialise NV (MTLS) Q2 2025 Earnings Call Transcript
Unknown7-24
The earnings call presents a mixed picture: strong growth in the Medical segment and improved gross margins are positive, but significant declines in Software and Manufacturing revenues, coupled with a net financial loss, are concerning. The Q&A reveals cautious optimism about future growth, but also highlights uncertainties, especially in the Manufacturing segment. The slight downward revision in guidance and management's vague responses further temper positive sentiment, resulting in a neutral outlook for the stock price.
MTLS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
